ClinicalTrials.gg
CompletedNCT04980248Updated Dec 27, 2024Results posted

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

A Phase 1 interventional study of ALXN1850 in Hypophosphatasia, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Hypophosphatasia by AstraZeneca — 4 open to participants now, 7 under way, 3 of them phase 3. Hypophosphatasia · AstraZeneca.

Enrollment
7th of 16
15 · median 13
Started
2021
the only one that year
Phase 1
2 of 25
none open now
Registered
18th of 25
by date

Among the 25 studies in Hypophosphatasia by AstraZeneca, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 1, and was the 18th registered.

Hypophosphatasia

46 studies on the registry are indexed under Hypophosphatasia; 11 are open to participants now.

Browse Hypophosphatasia studies →

Open to participants now

4 of the 25 studies in Hypophosphatasia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 9 Hypophosphatasia studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hypophosphatasia by AstraZeneca, or all of them as a file.
02

Study summary

This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.

03

Conditions studied

  • Hypophosphatasia

Browse trials for

Keywords

  • HPP
  • enzyme replacement therapy
  • low alkaline phosphatase
  • tissue-nonspecific alkaline phosphatase
  • TNSALP
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed clinical diagnosis of HPP
  • Not anticipated to require further treatment with enzyme replacement therapy to treat participant's HPP after study completion
  • Willing and able to follow protocol-specified requirements
  • Willing and able to give

Exclusion criteria

Exclusion Criteria:

  • Primary or secondary hyperparathyroidism or hypoparathyroidism
  • Fracture within 12 weeks of screening
  • Current or relevant history of unstable physical or psychiatric illness
  • Significant allergies
  • Asfotase alfa use within 6 months and/or positive for asfotase alfa antidrug antibody/neutralizing antibodies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    ALXN1850

    Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.

    Biological: ALXN1850

Interventions

  • BiologicalALXN1850

    ALXN1850 will be administered as an IV infusion and via the SC route.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    TEAEs were defined as any adverse events (AEs) that began or worsened on or after the first dose of treatment until the final follow-up visit. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. TESAEs were defined as any serious AEs that began or worsened on or after the first dose of treatment until the final follow-up visit. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Day 85

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of ALXN1850 Following Intravenous (IV) Dose, Subcutaneous (SC) Dose 1, SC Dose 2 and SC Dose 3

    Time frame: Predose, 2, 6 and 12 hours postdose on Days 1, 15, 22 and 29

  2. Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity Following IV Dose of ALXN1850

    Time frame: Predose, 2, 6 and 12 hours postdose on Days 1, 15, 22 and 29

  3. Area Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Following SC Dose 1, SC Dose 2 and SC Dose 3

    Time frame: Predose, 2, 6 and 12 hour postdose on Days 1, 15, 22 and 29

  4. Area Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Values of the First SC Versus IV Administration of ALXN1850

    Time frame: Predose, 2, 6 and 12 hour postdose on Days 1, 15, 22 and 29

  5. Absolute Change From Baseline in Plasma Concentration of Pyridoxal-5' Phosphate (PLP) at Week 1

    Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3

  6. Absolute Change From Baseline in Plasma Concentration of Inorganic Pyrophosphate (PPi) at Week 1

    Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3

  7. Absolute Change From Baseline in Plasma Concentration of Pyridoxal Phosphate/ Pyridoxal (PLP/PL) Ratio at Week 1

    Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3

  8. Percent Change From Baseline in Plasma Concentration of PLP at Week 1

    Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3

  9. Percent Change From Baseline in Plasma Concentration of PPi at Week 1

    Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3

  10. Percent Change From Baseline in Plasma Concentration of PLP/PL Ratio Over Time at Week 1

    Time frame: Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3

  11. Number of Participants With Anti-drug Antibody (ADA) Positive and Neutralizing Antibody (NAb) Positive Status

    Time frame: Baseline up to Day 85

07

Results

Posted Dec 27, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3
Started555
Received at least 1 dose of study drug555
Completed555
Not completed000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

TEAEs were defined as any adverse events (AEs) that began or worsened on or after the first dose of treatment until the final follow-up visit. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. TESAEs were defined as any serious AEs that began or worsened on or after the first dose of treatment until the final follow-up visit. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Day 85
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsCohort 1Cohort 2Cohort 3
TEAEs354
TESAEs001
SecondaryMaximum Observed Plasma Concentration (Cmax) of ALXN1850 Following Intravenous (IV) Dose, Subcutaneous (SC) Dose 1, SC Dose 2 and SC Dose 3
Time frame:
Predose, 2, 6 and 12 hours postdose on Days 1, 15, 22 and 29
Reported as:
Geometric mean · micrograms/milliliter
Maximum Observed Plasma Concentration (Cmax) of ALXN1850 Following Intravenous (IV) Dose, Subcutaneous (SC) Dose 1, SC Dose 2 and SC Dose 3
micrograms/milliliterCohort 1Cohort 2Cohort 3
IV Dose5.31 ± 29.213.5 ± 23.332.4 ± 31.1
SC Dose 10.871 ± 43.82.89 ± 59.48.60 ± 43.5
SC Dose 20.815 ± 52.32.38 ± 88.86.33 ± 55.5
SC Dose 30.844 ± 75.22.41 ± 97.45.44 ± 145
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity Following IV Dose of ALXN1850
Time frame:
Predose, 2, 6 and 12 hours postdose on Days 1, 15, 22 and 29
Reported as:
Geometric mean · hour*micrograms/milliliter
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity Following IV Dose of ALXN1850
hour*micrograms/milliliterCohort 1Cohort 2Cohort 3
Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity Following IV Dose of ALXN1850407 ± 38.31010 ± 26.02450 ± 33.6
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Following SC Dose 1, SC Dose 2 and SC Dose 3
Time frame:
Predose, 2, 6 and 12 hour postdose on Days 1, 15, 22 and 29
Reported as:
Geometric mean · hour*micrograms/milliliter
Area Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Following SC Dose 1, SC Dose 2 and SC Dose 3
hour*micrograms/milliliterCohort 1Cohort 2Cohort 3
SC Dose 1115 ± 42.2383 ± 58.11110 ± 49.6
SC Dose 2111 ± 58.5350 ± 83.3872 ± 65.5
SC Dose 3115 ± 73.9367 ± 95.6881 ± 104
SecondaryArea Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Values of the First SC Versus IV Administration of ALXN1850
Time frame:
Predose, 2, 6 and 12 hour postdose on Days 1, 15, 22 and 29
Reported as:
Geometric least squares mean · Ratio
Area Under the Plasma Concentration Versus Time Curve From Time 0 to Dosing Interval (AUCtau) Values of the First SC Versus IV Administration of ALXN1850
RatioAll Participants
15 mg0.286 (0.105 to 0.782)
45 mg0.367 (0.180 to 0.784)
90 mg0.368 (0.0908 to 1.49)
SecondaryAbsolute Change From Baseline in Plasma Concentration of Pyridoxal-5' Phosphate (PLP) at Week 1
Time frame:
Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Reported as:
Mean · nanogram/milliliter
Absolute Change From Baseline in Plasma Concentration of Pyridoxal-5' Phosphate (PLP) at Week 1
nanogram/milliliterCohort 1Cohort 2Cohort 3
1 Week post Day 1 IV Dose-18.300 ± NA-7.600 ± NA-49.460 ± NA
1 Week post Day 29 SC Dose 3-97.950 ± 164.0193-38.573 ± 26.4932-28.055 ± 17.3237
SecondaryAbsolute Change From Baseline in Plasma Concentration of Inorganic Pyrophosphate (PPi) at Week 1
Time frame:
Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Reported as:
Mean · micromoles (uM)
Absolute Change From Baseline in Plasma Concentration of Inorganic Pyrophosphate (PPi) at Week 1
micromoles (uM)Cohort 1Cohort 2Cohort 3
1 Week post Day 1 IV Dose-1.620 ± NA-1.930 ± NA—
1 Week post Day 29 SC Dose 3-0.813 ± 0.5970-1.505 ± 0.1202-2.040 ± NA
SecondaryAbsolute Change From Baseline in Plasma Concentration of Pyridoxal Phosphate/ Pyridoxal (PLP/PL) Ratio at Week 1
Time frame:
Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Reported as:
Mean · Ratio
Absolute Change From Baseline in Plasma Concentration of Pyridoxal Phosphate/ Pyridoxal (PLP/PL) Ratio at Week 1
RatioCohort 1Cohort 2Cohort 3
1 Week post Day 1 IV Dose-8.570 ± NA-16.070 ± NA-15.260 ± NA
1 Week post Day 29 SC Dose 3-7.620 ± 5.3878-15.285 ± 6.2807-8.368 ± 6.3951
SecondaryPercent Change From Baseline in Plasma Concentration of PLP at Week 1
Time frame:
Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Reported as:
Mean · percent change
Percent Change From Baseline in Plasma Concentration of PLP at Week 1
percent changeCohort 1Cohort 2Cohort 3
1 Week post Day 1 IV Dose-47.906 ± NA-17.512 ± NA-86.318 ± NA
1 Week post Day 29 SC Dose 3-33.895 ± 42.5254-69.049 ± 16.5385-70.515 ± 23.0447
SecondaryPercent Change From Baseline in Plasma Concentration of PPi at Week 1
Time frame:
Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Reported as:
Mean · percent change
Percent Change From Baseline in Plasma Concentration of PPi at Week 1
percent changeCohort 1Cohort 2Cohort 3
1 Week post Day 1 IV Dose-53.821 ± NA-70.956 ± NA—
1 Week post Day 29 SC Dose 3-32.740 ± 23.0615-55.328 ± 1.7622-71.329 ± NA
SecondaryPercent Change From Baseline in Plasma Concentration of PLP/PL Ratio Over Time at Week 1
Time frame:
Baseline, 1 Week post Day 1 IV dose and 1 Week post Day 29 SC dose 3
Reported as:
Mean · percent change
Percent Change From Baseline in Plasma Concentration of PLP/PL Ratio Over Time at Week 1
percent changeCohort 1Cohort 2Cohort 3
1 Week post Day 1 IV Dose-65.270 ± NA-92.944 ± NA-91.323 ± NA
1 Week post Day 29 SC Dose 3-35.104 ± 15.0384-77.160 ± 16.0636-60.816 ± 49.7578
SecondaryNumber of Participants With Anti-drug Antibody (ADA) Positive and Neutralizing Antibody (NAb) Positive Status
Time frame:
Baseline up to Day 85
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibody (ADA) Positive and Neutralizing Antibody (NAb) Positive Status
ParticipantsCohort 1Cohort 2Cohort 3
ADA Positive202
NAb Positive000

Adverse events

Collected over Baseline up to Day 85. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/5 (0%)0/5 (0%)3/5 (60%)
Cohort 20/5 (0%)0/5 (0%)5/5 (100%)
Cohort 30/5 (0%)1/5 (20%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2Cohort 3
Atrial fibrillationCardiac disorders0/50/51/5
Most frequent other events
Showing 10 of 30
Most frequent other events
EventCohort 1Cohort 2Cohort 3
HeadacheMusculoskeletal and connective tissue disorders1/52/50/5
Coronavirus infectionInfections and infestations0/51/52/5
HyperphosphataemiaMetabolism and nutrition disorders2/50/50/5
HaematuriaRenal and urinary disorders0/52/50/5
FatigueGeneral disorders1/51/50/5
Injection site bruisingGeneral disorders1/51/50/5
Injection site erythemaGeneral disorders0/51/51/5
Injection site haemorrhageGeneral disorders0/51/50/5
Injection site pruritusGeneral disorders0/51/50/5
Injection site reactionGeneral disorders1/50/50/5

Baseline characteristics

The Safety Set included all participants who received any amount of study drug. Participants were analyzed according to the study drug received.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Total
Mean44.2 ± 12.4437.8 ± 12.5254.6 ± 9.0745.5 ± 12.80
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female33511
Male2204
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
Hispanic or Latino0000
Not Hispanic or Latino55515
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White55515
More than one race0000
Unknown or Not Reported0000
08

Study locations

4 sites
  • Research Site
    Las Vegas, Nevada 89113, United States
  • Research Site
    Columbus, Ohio 43203, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Austin, Texas 78744, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Aug 2022, 10 months.

Results were first posted in Dec 2024, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2021
First posted
Jul 28, 2021
StartActual
Sep 28, 2021
Primary completionActual
Aug 24, 2022
CompletionActual
Aug 24, 2022
Results first posted
Dec 27, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04980248
Responsible party
Sponsor
First posted
Jul 28, 2021
Start date
Sep 28, 2021
Primary completion
Aug 24, 2022
Completion
Aug 24, 2022
Results posted
Dec 27, 2024
Last update
Dec 27, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efzimfotase alfa

Start the discussion